The study suggests that Semaglutide is effective in reducing symptoms and weight in patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes when compared to a placebo
HFpEF
REDUCE LAP-HF II: Atrial Shunt Device in HFpEF and HFmEF
Insights from the REDUCE LAP-HF II Trial: Atrial Shunt Devices in Heart Failure Management The REDUCE LAP-HF II Trial, published in 2022, was a significant randomized, blinded, sham-controlled trial aiming to enhance the treatment for patients with heart failure. It … Read More
The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent form of heart failure, accounting for nearly half of all heart failure cases. Despite its significance, HFpEF remains a challenging condition to manage and treat, as effective … Read More
PERSPECTIVE Trial Summary: Sacubitril/valsartan Effect on Cognition in HFpEF
2022 PERSPECTIVE TRIAL M Efficacy and safety of sacubitril/valsartan compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction parallel, randomized controlled trial Objective: To evaluate the effectiveness of sacubitril/valsartan compared with valsartan alone … Read More